 |
Human alpha 2,6 sialyltransferase adenoviral gene therapy |
|---|---|
| Trade Name | |
| Orphan Indication | Patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase |
| USA Market Approval | USA |
| USA Designation Date | 2005-04-04 00:00:00 |
| Sponsor | Falk Center for Molecular Therapeutics;1801 Maple Avenue, Suite 4300;Evanston, Illinois, 60201 |
